Overall, our findings indicate that GFPT2 plays a pivotal role in modulating the NF-κB signaling pathway, which impacts paclitaxel resistance in ovarian cancer and highlights its broader implications in tumor progression and inflammatory responses. This evidence concerns the gene NFKB1 and ovarian carcinoma.